Vanda Pharmaceuticals Inc. — All Filings
1,000 total filings on record
Public companies registered with the SEC are required to file periodic reports, disclosures, and notices throughout the year. The most important are the 10-K (annual report), 10-Q (quarterly report), and 8-K (material event notice). Use the filters below to narrow by form type.
All
10-K
10-K/A
10-Q
144
3
4
4/A
424B4
424B5
5
8-A12B
8-A12B/A
8-A12G
8-K
8-K/A
ARS
ARS/A
CORRESP
CT ORDER
DEF 14A
DEFA14A
DFAN14A
EFFECT
PREC14A
S-1
S-1/A
S-1MEF
S-3
S-3/A
S-3MEF
S-8
SC 13D
SC 13D/A
SC 13G
SC 13G/A
SCHEDULE 13G
SCHEDULE 13G/A
UPLOAD
| Form | Description | Accession Number | Filed | Period |
|---|---|---|---|---|
| 8-K | 8-K | 0001628280-25-023154 | May 7, 2025 | — |
| ARS | ARS | 0001628280-25-019996 | Apr 25, 2025 | Dec 31, 2024 |
| DEF 14A | DEF 14A | 0001628280-25-019987 | Apr 25, 2025 | Jun 5, 2025 |
| DEFA14A | DEFA14A | 0001628280-25-019992 | Apr 25, 2025 | — |
| SCHEDULE 13G | — | 0002052113-25-000361 | Apr 15, 2025 | — |
| 8-K | 8-K | 0001193125-25-055287 | Mar 17, 2025 | Mar 14, 2025 |
| 4 | 4 | 0000950170-25-034966 | Mar 6, 2025 | — |
| 4 | 4 | 0000950170-25-033845 | Mar 5, 2025 | — |
| 4 | 4 | 0000950170-25-032270 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032273 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032276 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032281 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-032285 | Mar 4, 2025 | Mar 1, 2025 |
| 4 | 4 | 0000950170-25-030176 | Feb 28, 2025 | — |
| 4 | 4 | 0000950170-25-029059 | Feb 27, 2025 | — |
| 4 | 4 | 0000950170-25-027860 | Feb 26, 2025 | — |
| 4 | 4 | 0000950170-25-027056 | Feb 25, 2025 | — |
| 4 | 4 | 0000950170-25-025914 | Feb 24, 2025 | Feb 21, 2025 |
| 4 | 4 | 0000950170-25-024489 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024498 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024487 | Feb 20, 2025 | Feb 18, 2025 |
| 8-K | 8-K | 0001193125-25-030780 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024485 | Feb 20, 2025 | Feb 18, 2025 |
| 4 | 4 | 0000950170-25-024486 | Feb 20, 2025 | Feb 18, 2025 |
| 10-K | 10-K | 0001628280-25-005761 | Feb 14, 2025 | Dec 31, 2024 |
| 8-K | 8-K | 0001628280-25-005406 | Feb 13, 2025 | — |
| SCHEDULE 13G/A | — | 0002052113-25-000166 | Feb 7, 2025 | — |
| SCHEDULE 13G/A | — | 0002012383-25-001341 | Feb 5, 2025 | — |
| 8-K | 8-K | 0001193125-25-012740 | Jan 27, 2025 | Jan 25, 2025 |
| 4 | 4 | 0000950170-24-128115 | Nov 18, 2024 | Nov 14, 2024 |
| 144 | — | 0000950170-24-127062 | Nov 14, 2024 | — |
| 10-Q | 10-Q | 0001628280-24-045970 | Nov 7, 2024 | Sep 30, 2024 |
| 8-K | 8-K | 0001628280-24-045724 | Nov 6, 2024 | — |
| 8-K | 8-K | 0001193125-24-237220 | Oct 15, 2024 | Oct 14, 2024 |
| 8-K | 8-K | 0001193125-24-232306 | Oct 3, 2024 | Oct 2, 2024 |
| 8-K | 8-K | 0001193125-24-221784 | Sep 19, 2024 | — |
| 8-K | 8-K | 0001193125-24-196481 | Aug 8, 2024 | Aug 7, 2024 |
| 8-A12B/A | 8-A12B/A | 0001193125-24-196495 | Aug 8, 2024 | — |
| 10-Q | 10-Q | 0001628280-24-033866 | Aug 1, 2024 | Jun 30, 2024 |
| 8-K | 8-K | 0001628280-24-033743 | Jul 31, 2024 | — |
| 144 | — | 0000950170-24-087370 | Jul 29, 2024 | — |
| 4 | 4 | 0000950170-24-087381 | Jul 29, 2024 | — |
| 8-K | 8-K | 0001193125-24-164545 | Jun 20, 2024 | Jun 19, 2024 |
| 8-K | 8-K | 0001193125-24-160755 | Jun 13, 2024 | — |
| 8-K | 8-K | 0001193125-24-156117 | Jun 6, 2024 | — |
| 8-K | 8-K | 0001628280-24-025254 | May 24, 2024 | — |
| 8-K/A | 8-K/A | 0001628280-24-025241 | May 24, 2024 | May 17, 2024 |
| 4 | 4 | 0000950170-24-064669 | May 24, 2024 | May 22, 2024 |
| 4 | 4 | 0000950170-24-063015 | May 21, 2024 | May 17, 2024 |
| 4 | 4 | 0000950170-24-063017 | May 21, 2024 | May 17, 2024 |